In contrast, DHL-BCL6 patients display diverse molecular subtypes and comparable survival outcomes to those with DLBCL-NOS, responding well to both R-CHOP and R-DA-EDOCH regimens. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.